<DOC>
	<DOCNO>NCT01079741</DOCNO>
	<brief_summary>The incidence melanoma increase estimate incidence 59,940 case annual death rate 8110 2007 . Although patient diagnose early stage disease excellent clinical outcome , patient diagnose advanced recurrent disease , continue high mortality rate , even initial optimal surgical resection . Effective adjuvant strategy need increase time progression decrease recurrence rate . Immunotherapy long recognize potential therapy melanoma ; goal adjuvant vaccine therapy train endogenous immune system recognize target minimal residual disease .</brief_summary>
	<brief_title>Safety Study Adjuvant Vaccine Treat Melanoma Patients</brief_title>
	<detailed_description>This Phase I open label dose escalation study TLR3 agonist Poly-ICLC adjuvant NY-ESO-1 protein vaccination patient high risk melanoma clinical complete remission ( cCr ) , follow randomized Phase II component patient randomize subcutaneous vaccination NY-ESO-1 protein Poly-ICLC alone dose TBD ( Arm A ) NY-ESO-1 protein , Poly-ICLC dose TBD MontanideÂ® ISA-51 VG ( Montanide ) ( Arm B ) . Patients histological confirm malignant melanoma , AJCC Stages : IIB , IIC , III IV , complete clinical remission ( cCr ) high risk disease recurrence , eligible enrollment , regardless whether antigen expression autologous tumor demonstrate either PCR immunohistochemistry . Primary Objectives : - Phase I : To define safety subcutaneous vaccination NY-ESO-1 protein , Montanide escalate dos Poly-ICLC . - Phase II : To evaluate induction humoral T cell ( CD4+ CD8+ ) immunity subcutaneous vaccination NY-ESO-1 protein combination Poly-ICLC give without Montanide . Exploratory analysis : - Evaluation primary tumor expression NY-ESO-1 IHC RT-PCR . - Histologic quantitation original tumor TILs ( tumor infiltrate lymphocyte ) , CD3+ cell , evaluation mitotic index correlation data immunologic response . - Correlation NY-ESO-1 specific T cell response HLA type - Investigation polymorphism TLR3 germline SNP analysis . - Clinical Outcome ( Time Progression ) report descriptively . - Skin section analysis protein/adjuvant treat site immune cell infiltration gene expression analysis</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Inclusion Criteria 1 . Histological diagnosis malignant melanoma , stag IIBIV radiologically confirm cCr without clinical evidence disease . 2 . At least 4 week since surgery prior first dose study agent . 3 . Laboratory value within follow limit : 1 . Hemoglobin &gt; 10.0 g/dL 2 . Neutrophil count &gt; 1.5 x l09/L 3 . Lymphocyte count &gt; Lower limit institutional normal 4 . Platelet count &gt; 80 x l09/L 5 . Serum creatinine &lt; 2.0 mg/dL 6 . Serum bilirubin &lt; 2 x upper limit institutional normal 7 . AST/ALT &lt; 2 x upper limit institutional normal 4 . Patients must ECOG performance status &lt; 2 ( ECOG criterion publish [ 67 ] . 5 . Life expectancy &gt; 6 month . 6 . Age &gt; 18 year . 7 . Able willing give write informed consent participation trial ( see Section 12.2 ) . Exclusion Criteria 1 . Serious illness , e.g. , serious infection require antibiotic . 2 . Previous bone marrow stem cell transplant . 3 . History immunodeficiency disease ( HIV ) autoimmune disease except vitiligo . 4 . Metastatic disease central nervous system . 5 . Other malignancy within 3 year prior entry study , except treat earlystage melanoma nonmelanoma skin cancer , cervical carcinoma situ . 6 . Prior chemotherapy vaccine therapy . 7 . Radiation therapy , biological therapy surgery within 4 week prior first dose study agent . 8 . Concomitant treatment systemic corticosteroid great physiologic dos . Topical ( propose vaccination site ) inhalational steroid permit . 9 . Participation clinical trial involve another investigational agent within 4 week prior first dose study agent . 10 . Pregnancy lactation . 11 . Women childbearing potential use medically acceptable mean contraception . 12 . Psychiatric addictive disorder may compromise ability give informed consent . 13 . Lack availability patient immunological clinical followup assessment . 14 . Children &lt; 18 year age undergo leukapheresis procedure , meet disease stag and/or size criterion frequent blood donation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Oncogenesis</keyword>
	<keyword>LAGE</keyword>
	<keyword>Cancer Immunity</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>